Study evaluates rituximab as ANCA vasculitis therapy

08/1/2013 | Medscape (free registration)

Short-term rituximab had outcomes that were comparable to 18 months of using cyclophosphamide and azathioprine in the treatment of severe antineutrophil cytoplasmic antibody-associated vasculitis, according to a study in the New England Journal of Medicine. At 18 months, 39% of patients in the rituximab group were in complete remission, compared with 33% in the standard treatment group.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
South San Francisco, CA
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD